Whether Letrozole could reduce the incidence of early ovary hyperstimulation syndrome after assisted reproductive technology? A systematic review and meta-analysis

Jing Zhao, Bin Xu, Xi Huang, Yi Yan and Yanping Li*

Abstract
Background: Letrozole can significantly decrease the estrogen level, and has been administrated to prevent the incidence of early ovary hyperstimulation syndrome (OHSS). However, the effect of Letrozole on prevention of OHSS reached to controversial conclusions. The present meta-analysis aim to examine whether Letrozole could reduce the incidence of early OHSS after assisted reproductive technology (ART).

Methods: An exhaustive electronic literature search was conducted on MEDLINE, Google Scholar, CNKI and WANFANG MED ONLINE, from inception until May 2018. We include clinical trials that examined the effect of Letrozole on the prevention of early OHSS. The main outcome measures were the incidence of total early OHSS, mild early OHSS, moderate early OHSS, and severe early OHSS.

Results: Eight studies included in the review. Of these, five publications evaluated the effect of Letrozolel on the prevention of total, mild, moderate, and severe OHSS, respectively. The results indicated that there was a significantly decreased incidence of total OHSS with Letrozole compared with control group, and there were no significantly differences in the incidence of mild, moderate, and severe OHSS between study group with Letrozole and control group. Eight studies reported the incidence of moderate + severe OHSS. We found a significant decrease in incidence of moderate + severe OHSS in high-risk women with Letrozole.

Conclusions: Letrozole has no beneficial effect on the prevention of mild, moderate, and severe OHSS, individually; Letrozole should not be considered as the first-line treatment for prevention of OHSS. Further cohort studies are required to explore the effect of Letrozole on the prevention of OHSS.

Plain English Summary: This study aimed to examine whether Letrozole could reduce the incidence of early OHSS after assisted reproductive technology (ART). A meta-analysis including 8 studies was conducted. There were no significantly differences in the incidence of mild, moderate, and severe OHSS between study group with Letrozole and control group. Letrozole has no beneficial effect on the prevention of mild, moderate, and severe OHSS, individually.

Keywords: Ovarian hyperstimulation syndrome, Letrozole, Assisted reproductive technologies
**Background**

Ovarian hyperstimulation syndrome (OHSS) is a serious iatrogenic complication resulted by controlled ovarian stimulation (COS) during assisted reproductive technology (ART). It was reported that 3.1–8.0% of in vitro fertilization (IVF) cycles developed into moderate to severe OHSS, and the incidence rate has reached to 20% in women at high-risk [1]. The clinical manifestation of OHSS includes enlarged ovarian volume, abdominal tenderness and swelling, which caused by an increased vascular permeability and effusion to the extravascular space. Lyons et al. [2] described 2 forms of OHSS for the first time: the early and late forms. The early OHSS happened within 9 days after HCG trigger and the late OHSS occurs 10 days after HCG trigger and is always associated with endogenous HCG level after pregnancy.

Vascular endothelial growth factor (VEGF) plays a crucial part in the development of OHSS [3, 4]. Besides, other systematic and local vasoactive substances are also directly and indirectly involved in the pathogenesis of OHSS symptoms [3, 5–9]. At present, there have no effective methods that can treat moderate and severe OHSS, so prevention seems very important [10]. For the women at high-risk of OHSS, an important means to prevent OHSS is to cryopreserve all fresh embryos [11, 12]. However, only late OHSS can be avoided by fresh embryo cryopreservation, but early OHSS cannot be prevented [13]. A number of strategies have been suggested to reduce the incidence of OHSS, such as coating [14], GnRH-ant protocol with GnRH-a for trigger [15, 16], HES [17, 18], human albumin [19], aspirin [20, 21], dopamine agonist [22], calcium [23], metformin [24], aspiration of pleural effusion [25].

As we all known, elevated serum estrogen concentrations have been correlated with a higher incidence of OHSS [26]. Letrozole is a nonsteroidal aromatase inhibitor, and can inhibit the conversion of androgens into estrogens by blocking the aromatase and E synthetase in a potent, specific, and reversible way [27]. One study showed that administering Letrozole after oocyte retrieval could reduce E2 level and restore LH production, and proposed that Letrozole may be used to reduce the OHSS incidence [28, 29]. In the following years, several clinical trials have evaluated the effect of Letrozole on the prevention of early OHSS in high-risk women. Some studies have reported that Letrozole can reduce the incidence of early OHSS [30–34]. However, some studies have showed that Letrozole can only reduce the E2 level, but failed to prevent the occurrence of OHSS [35–37]. So whether the Letrozole should be given to prevent OHSS reached to controversial conclusions, which made both clinicians and infertile women in an awkward position.

In the present systematic review, we aim to further evaluate whether Letrozole have effect on the prevention of early OHSS during ART in high-risk women and perform a systematic review and meta-analysis of the available literatures.

**Materials and methods**

**Identification of the literature**

Electronic databases including MEDLINE, Google Scholar, CNKI and WANFANG MED ONLINE, were searched from inception until May 2018. The key words used to search relative studies were as follows: one including terms on Letrozole (“Letrozole”, “Aromatase inhibitor”), one including terms on OHSS (“ovulatory hyperstimulation syndrome”, “OHSS”), and the last one about reproductive technologies (“IVF”, “ICSI”, “ART”, “in vitro fertilization”, “intracytoplasmic sperm injection”, “assisted reproductive technology”). A subset of citations related to the present question were generated by combining these subsets with “AND”. Two authors independently evaluated the eligibility of the articles, and group discussion was needed when there was a discrepancy.

**Study selection and data extraction**

Studies that administered Letrozole to prevent the OHSS in high-risk women undergoing COS were selected. The primary outcome was the incidence of total OHSS, the incidence of mild, moderate and severe OHSS. For studies to be eligible, outcome data were extracted in 2 × 2 tables. We also recorded the study type, treatment of ART, the ovary stimulation protocol, and the inclusion criteria of women. The quality of the included studies was evaluated by two authors with the Newcastle–Ottawa Quality Assessment Scales [38], a third author is needed if there was any disagreements about inclusion.

**Statistical analysis**

The comparisons of included studies were analyzed by a standard meta-analytic method, and the combined results were expressed with the odds relatives (ORs) and its 95% confidence interval (CI). Heterogeneity of the studies was evaluated graphically using Forest plot and statistically using the $I^2$ to quantify heterogeneity between studies. A fixed effect model or a random effect model was implied to calculate an overall OR and its 95% CI. Statistical analyses were carried out with RevMan 5.0 (Cochrane Collaboration). The results were considered to be statistically significant when the P value was < 0.05.

**Results**

**Studies selection and characteristics**

216 articles were yielded with the above search strategy. Of there, 199 were not relevant after reviewing the
titles and abstracts. Of the 17 remaining studies, one were excluded because the incidence of OHSS was not reported; Two studies have no full-text available. Three studies were excluded because all their data were duplications of another three studies that have been included in our review; an additional three articles were excluded because of lack of a 2 × 2 table. (Fig. 1).

The total number of eligible studies included in the review was 8, comprising 1551 women. Of these, five publications including 1215 women evaluated the effect of Letrozole administration on the prevention of total OHSS and mild OHSS. Five studies including 770 women reported the incidence of moderate OHSS and severe OHSS. Eight studies reported the incidence of moderate + severe OHSS.

The studies’ characteristics are summarized in Table 1. Of these 8 articles, 6 were prospective studies, and 2 were retrospective. All the studies used long GnRH-a protocol. Four studies only used Letrozole in the study group, and other four studies used both Letrozole and other treatments at the same time. As for the control group, three studies received oral placebo or no medication, and other
| Study            | Type of study | Treatment | Protocol                | Inclusion criteria                                                                                       | Usage of letrozole                                | Control                  | Standard for OHSS | Outcome         |
|------------------|---------------|-----------|-------------------------|---------------------------------------------------------------------------------------------------------|--------------------------------------------------|--------------------------|-------------------|-----------------|
| He et al. [32]   | Prospective   | IVF, ICSI | Standard long protocol  | No. of oocyte retrieval ≥ 25<br>E2 ≥ 6000 pg/ml on the HCG day<br>Ovary diameter ≥ 10 cm<br>Puncture follicle No. ≥ 30 | 2.5 mg qd / 2.5 mg bid / 2.5 mg tid, for 5 days | Oral placebo for 5 days | Golan et al         | Moderate and severe |
| Wang et al. [36] | Prospective   | IVF       | Long mid-luteal GnRH-a protocol | No. of oocyte retrieval ≥ 20<br>No. of follicles greater than 14 mm ≥ 20<br>E2 ≥ 8000 pg/ml on the HCG day<br>Ovary diameter ≥ 10 cm | 2.5 mg p.o. Bid for 5 days | Receive no special medication | Golan et al         | Mild, moderate, severe |
| Mai et al. [30]  | Prospective   | IVF, ICSI, PGD | Midluteal long GnRH-a protocol/short GnRH-a suppressive protocol | Oocyte retrieval ≥ 25<br>Estradiol level ≥ 5000 pg/ml<br>Clinical or ultrasonographic evidence of OHSS | 2.5 mg p.o. Bid for 5 days | Aspirin 100 mg qd, for 5 days | Navot D, et al | Mild, moderate, severe |
| Wang et al. [35] | Prospective   | IVF       | Long mid-luteal GnRH-a protocol | No. of oocyte retrieval ≥ 25<br>No. of follicles greater than 14 mm ≥ 25<br>E2 ≥ 8000 pg/ml on the HCG day<br>Ovary diameter ≥ 10 cm | Letrozole 2.5 mg p.o. Bid for 5 days + support therapy | Receive support therapy alone | Golan et al         | Mild, moderate, severe |
| Lin et al. [37]  | Retrospective | IVF, ICSI | Long mid-luteal GnRH-a protocol | E2 ≥ 7000 pg/ml on the HCG day<br>7000 pg/ml ≥ E2 ≥ 5000 pg/ml, and No. oocytes retrieval is 15 ~ 20, and abdominal distension<br>No. of oocyte retrieval ≥ 20 | Letrozole 2.5 mg p.o. Bid for 5 days + HES + prednisone 5 mg tid | Hydroxyethyl starch (HES) + prednisone 5 mg tid | No mention          | Moderate and severe |
| Study          | Type of study | Treatment | Protocol                              | Inclusion criteria                                                                 | Usage of letrozole        | Control                                      | Standard for OHSS | Outcome                      |
|---------------|---------------|-----------|---------------------------------------|-------------------------------------------------------------------------------------|--------------------------|----------------------------------------------|-------------------|-------------------------------|
| Yu [33]       | Prospective   | M, F, ICSI| Long mid-luteal GnRH-a protocol       | No. of oocyte retrieval > 20, E2 > 17765 pmol/l, No. of follicles > 20, Ovary diameter ≥ 10 cm, Other severe clinical manifestations | Letrozole + HES + Ca     | HES + Calcium gluconate (Ca)                 | Golan et al       | Total OHSS, moderate and severe |
| Golan et al   | Mild, Moderate, severe | M, F, ICSI| GnRH-a long protocol / ultra-long protocol | No. of oocyte retrieval ≥ 20, E2 ≥ 25620 pmol/L, Obvious abdominal distension, Ovary diameter ≥ 10 cm | Letrozole 2.5 mg p.o. tid + HES | HES                             | Golan et al       | Moderate, severe              |
| Zhang et al. [34] | Retrospective | M, F, ICSI| No. of oocyte retrieval ≥ 20, E2 ≥ 25620 pmol/L, Obvious abdominal distension, Ovary diameter ≥ 10 cm | Letrozole 2.5 g bid, for 5 days | Placebo bid for 5 days | HES + Calcium gluconate (Ca) | Golan et al       | Moderate, severe              |
| He et al. [31] | Prospective   | M, F, ICSI| Standard long protocol                | No. of oocyte retrieval ≥ 20, E2 ≥ 2000 pmol/L, No. of follicles greater than 14 mm ≥ 30, Ovary diameter ≥ 10 cm | Letrozole 2.5 g bid, for 5 days | Placebo bid for 5 days | Golan et al       | Moderate, severe              |
drugs were administered in control group of the other five studies. Six of these studies evaluated the severity of OHSS according to the study by Golan et al. [39], one study according to Navot’s study [40], and another one study did not mention it.

Meta-analysis
At first, we evaluated the effect of Letrozole administration on the prevention of mild OHSS after ART. Five studies were included in our meta-analysis. The result indicated a significantly decreased incidence of total OHSS with administration of Letrozole compared with control group (OR 0.45; 95% CI 0.31, 0.64; P < 0.00001), and there was good statistical heterogeneity in the results (I² = 0%, P = 0.99) (Fig. 2).

The above five studies also evaluated the effect of Letrozole administration on the prevention of mild OHSS after ART at the same time. After analysis, we found that there was no significantly difference in the incidence of mild OHSS between study group with Letrozole administration and control group with no medication or other treatment. The Q statistic P value was < 0.05, indicating heterogeneity of the studies (I² = 80%, P = 0.0006). The random effects model was used and the combined OR was 1.21 (95% CI 0.63, 2.31; P = 0.57) (Fig. 3).

The effect Letrozole administration on the prevention of moderate OHSS was also evaluated. Five studies with 770 women were included outcomes. The results indicated that there was no significantly difference in incidence of moderate OHSS between study group with Letrozole administration and control group with no medication or other treatments (OR 0.60; 95% CI 0.33, 1.09; P = 0.09) (Fig. 4). The studies evaluating the incidence of moderate OHSS showed moderate heterogeneity (I² = 53%, P = 0.07).

When we evaluated the effect of Letrozole on the prevention of severe OHSS after ART in high-risk women, five studies were included. The result of the meta-analysis showed that there was similar incidence of severe OHSS between study group with Letrozole administration and the control group with or without other treatments. There exist heterogeneity of the studies (I² = 67%, P = 0.02), as the Q statistic P-value was below 0.05. We implied the random effects model and the combined OR was 0.76 (95% CI 0.27, 2.21; P = 0.62) (Fig. 5).

Eight studies were included to assess the effect of Letrozole on the prevention of moderate + severe OHSS after ART. We found a significant decreased incidence of moderate + severe OHSS in high-risk women with Letrozole compared with those with or without other medication in the control group. The Q statistic P value was 0.05, showing heterogeneity of the studies (I² = 50%, P = 0.05). The random effects model combined odds ratio (OR) was 0.47 (95% CI 0.30–0.74; P = 0.001) (Fig. 6).

The studies have got good marks with the Newcastle–Ottawa Quality Assessment Scale (not shown). The funnel plots evaluating the effect of Letrozole on the prevention of total OHSS, mild, severe, and moderate + severe OHSS suggest lack of publication bias, thanks to their symmetrical shape (Additional file 1: Figure S1, Additional file 2: Figure S2, Additional file 3: Figure S3, Additional file 4: Figure S4). However, the study indicated modest publication bias when assessing the effect of Letrozole on the prevention of moderate OHSS (Additional file 5: Figure S5).

Discussion
To the best of our knowledge, the present study is the first systematic review and meta-analysis, which assess the effect of Letrozole on the prevention of early OHSS after ART. Many studies have explored the effect of Letrozole administration on prevention of OHSS after ovary stimulation during IVF/ICSI/PGD treatment cycles. Several studies found that Letrozole administration after oocyte retrieval could decrease the incidence of OHSS [30–34], while other studies did not show a decreased incidence of OHSS after ART with Letrozole administration [35–37]. In the present review and meta-analysis, 5, 5, 5, 5 and 8 studies were included to assess the effect of Letrozole administration on the prevention of total OHSS, mild OHSS, moderate OHSS, severe OHSS, and moderate-severe OHSS, respectively.

The results have demonstrated that the Letrozole administration could significantly decrease the incidence of total OHSS, the pooled OR was 0.45 (95% CI 0.31, 0.64). When we classify the OHSS into mild, moderate, and severe OHSS according to the severity, the results indicated that all kinds of OHSS seems cannot be prevented by Letrozole administration, the pooled ORs was 1.21 (95% CI 0.63, 2.31) for mild OHSS, 0.60 (95% CI 0.33, 1.09) for moderate OHSS, 0.76 (95% CI 0.27, 2.21). The incidence of moderate and severe OHSS showed a decreased tendency, but there were no significantly difference between study group with Letrozole administration and control group with no medication or other treatments.

In the clinical practice, there is no clear boundary between the moderate OHSS and the severe OHSS, and the moderate OHSS would develop into severe OHSS in a short time. So we in further evaluate whether Letrozole administration could decrease the incidence of the moderate + severe OHSS. Eight studies with 1551 women were included. The pooled OR was 0.47 with 95% CI 0.30, 0.74, indicating beneficial effect of Letrozole administration on prevention of combined moderate + severe
Fig. 2 Forest plot showing the results of meta-analysis of studies evaluating the effect of letrozole administration on prevention of total early OHSS after ART.

Fig. 3 Forest plot showing the results of meta-analysis of studies evaluating the effect of letrozole administration on prevention of mild early OHSS after ART.

Fig. 4 Forest plot showing the results of meta-analysis of studies evaluating the effect of letrozole administration on prevention of moderate early OHSS after ART.

Fig. 5 Forest plot showing the results of meta-analysis of studies evaluating the effect of letrozole administration on prevention of severe early OHSS after ART.
The difference between combined and individual analysis may attribute to the sample size. The characteristic of OHSS is multi-follicular development, enlarged ovarian, and high E2 [41, 42]. The serum E2 level on the day of HCG injection is an important indicator to predict the occurrence of OHSS [43]. When the level of E2 is more than 6000 pg/ml, the incidence rate of severe OHSS can up to 38% [44]. During COS, “coasting” program (Gn is stopped for several days) was used to reduce the level of E2 to safe concentration, and the HCG was administrated to induce oocyte final maturation, leading to decreased incidence of OHSS in the women at a high-risk [45]. This indicated that the serum E2 level is strongly related with the incidence of OHSS.

As a non-steroidal aromatase inhibitor, Letrozole can block the human aromatase, and inhibit androgens from converting to estrogens, thereby decreasing the E2 level [46]. At first, Letrozole was used in patients with E2-dependent tumors, such as breast cancer, and was used to induce ovulation [47]. In recent years, Letrozole was gradually applied in women with high risk OHSS. It is well known that the Letrozole can decrease the E2 level, but it is conflict whether Letrozole can decrease the incidence of OHSS.

In 2008, Fatemi reported that E2 level was significantly decreased after 5.0 mg Letrozole administration during luteal phase compared with placebo group [29]. In 2009, Garcia-Velasco reported that 2.5 mg of Letrozole can significantly decreased E2 during luteal phase, which was consistent with the pharmacological mechanism of Letrozole, and proposed that it could be used to prevent the OHSS [28].

Recently, some studies have tried Letrozole to prevent the occurrence of early OHSS. One study explored the effect of different doses of Letrozole on the incidence of OHSS after oocyte retrieval during IVF in patients with high-risk OHSS, and showed that 2.5 mg, 5.0 mg, and 7.5 mg daily for 5 days can decrease the level of E2 and VEGF to some extent in patients at high-risk for OHSS. The incidence of OHSS was slightly decreased with 2.5 mg and 5 mg Letrozole, and was significantly decreased with 7.5 mg Letrozole, indicating that 7.5 mg Letrozole may be useful to limit OHSS [31]. In 2017, another study by Mai compared the effect of Letrozole with aspirin in prevention of early OHSS, and found that Letrozole was more effective than aspirin in decreasing the incidence of moderate and severe early-onset OHSS. In this study, author indicated that OHSS might be caused by a luteolytic effect rather modulation of VEGF [30].

However, Wang described that 5 mg of Letrozole during luteal phase can significantly decrease serum E2 levels on the 2nd, 5th, and 8th days after oocyte retrieval compared with the control group, but it could not decrease the incidence of severe OHSS [35]. Two years later, her team explored the effect of ovarian steroid hormone suppression during luteal phase after oocyte retrieval on prevention of severe OHSS in high-risk women with all fresh embryo cryopreservation, and showed that steroidal ovarian suppression with Letrozole or mifepristone or cetrotide seems not to be able to prevent severe OHSS [36].

At present, the guideline for “Prevention and Treatment of moderate and severe ovarian hyperstimulation syndrome” has not commended Letrozole to prevent OHSS [48]. So it is very necessary to do the present systematic review and meta-analysis. Interestingly, the present study showed that Letrozole could decrease the incidence of total OHSS and moderate + severe OHSS, whereas have no effect on the prevention of occurrence of mild, moderate, and severe OHSS, individually. This is consistent with results reported by Wang et al. [35, 36].

The possible explanations for our results were as follows: Firstly, the sample size was relative small when...
three kinds of OHSS were evaluated individually. Secondly, Letrozole have no effect on prevention of OHSS. As Wang have state, high E2 level could only predict the occurrence of OHSS, and is not the reason for OHSS, so decreased E2 level during luteal phase could not prevent the incidence of OHSS. Thirdly, exuberant secretion from multiple corpus luteum after superovulation can cause the high E2 levels observed during the luteal phase. From the point of pathogenesis and pathophysiology, aromatase inhibitor administration during the luteal phase cannot completely prevent OHSS.

VEGF serum levels are associated with the likelihood of developing OHSS and with clinical feature [49, 50]. After stimulated by HCG, granulosa-lutein cells produce and release high level of VEGF, which interact with VEGF receptor in the endothelial cells membrane. A study by He et al. found that Letrozole significantly decreases the VEGF level, and the VEGF level and the incidence of moderate and severe OHSS decreased with the increase dose of Letrozole [31]. Mai et al’s study found that the VEGF level was significantly higher in Letrozole group compared with the aspirin group on HCG plus 7 days [30]. Regrettably, not all studies included in our meta-analysis have detected the expression of VEGF. The association between Letrozole administration and the level of VEGF still need further study.

A strength of systematic reviews is the more precision estimate with pooled ORs than the individual studies. The combined estimate indicated that Letrozole administration could decrease the incidence of total OHSS and moderate + severe OHSS, however have no effect on prevention of mild, moderate, and severe OHSS, individually. In addition, there were also some limitations. A major drawback of the present systematic review was the significant heterogeneity among these included studies’ characteristics: different study type (Prospective / Retrospective), different treatment type (IVF/ICSI/PGD), different dose of Letrozole administration (2.5 mg/5.0 mg/7.5 mg), and different treatments in control group (Aspirin/HES/Ca/Placebo). Besides, small sample size of study and lack of adjustment for meaningful confounders were the limitations of the present review. Although there were many drawbacks, the present systematic review and meta-analysis come into a valuable summary of the results of scientific publication so far.

**Conclusion**

The findings of this systematic review demonstrated that Letrozole administration after oocyte retrieval in high-risk women has no beneficial effect on the prevention of mild, moderate, and severe OHSS, individually; whereas could decrease the total incidence of moderate + severe OHSS. As the number of events in some studies is relatively small and the characteristics of studies are diversity, Letrozole should not be considered as the first-line treatment for prevention of OHSS. Further cohort studies are needed to explore the effect of administration on the prevention of OHSS.

**Supplementary information**

**Abbreviations**

ART: Assisted reproductive technology; CI: Confidence interval; ICSI: Intracytoplasmic sperm injection; OHSS: Ovary hyperstimulation syndrome; OR: Odds ratio.

**Acknowledgements**

Not applicable.

**Authors’ contributions**

ZJ contributed to electronic databases search, studies selection, data extraction. ZJ also involved in statistical analysis and drafting the article. YY and HX contributed substantially to the interpretation of the data and provided statistical support. XB helped with collecting data, drafting and revision of the article. LY contributed to conception and design, acquisition of data and analysis and interpretation of data. All authors read and approved the final manuscript.

**Funding**

This project was supported by the National Natural Science Foundation of China (Grant No. 81401269).

**Availability of data and materials**

The datasets supporting the conclusions of this article are included within the article and its additional file.

**Ethics approval and consent to participate**

Not applicable.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

Received: 1 March 2019   Accepted: 10 November 2020
Published online: 20 November 2020
References

1. Delvigne A, Rozenberg S. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Hum Reprod Update. 2002;8:559–77.

2. Lyons CA, Wheeler CA, Frishman GN, Hackett RJ, Seifer DB, Haning RV Jr. Early and late presentation of the ovarian hyperstimulation syndrome: two distinct entities with different risk factors. Hum Reprod. 1994;9:792–9.

3. Geva E, Jaffe RB. Role of vascular endothelial growth factor in ovarian physiology and pathology. Fertil Steril. 2000;74:429–38.

4. Levin ER, Rosen GF, Cassidenti DL, Yee B, Meldrum D, Wisot A, et al. Role of vascular endothelial cell growth factor in ovarian hyperstimulation syndrome. J Clin Invest. 1998;102:1978–85.

5. Pellicer A, Albert C, Mercader A, Bonilla-Musoles F, Remohi J, Simon C. The pathogenesis of ovarian hyperstimulation syndrome: in vivo studies investigating the role of interleukin-1b, interleukin-6, and vascular endothelial growth factor. Fertil Steril. 1999;71:482–9.

6. Whelan JG, Vlahos NF. The ovarian hyperstimulation syndrome. Fertil Steril. 2000;73:883–96.

7. Revel A, Barak Y, Lavy Y, Antebiy E, Abramov Y, Schenker JJ, et al. Characterization of intraportaloidal cytokines and nitrites in women with severe ovarian hyperstimulation syndrome. Fertil Steril. 1996;66:66–71.

8. Delbaere A, Bergmann PJM, Gervy-Destenter D, Schachtschneider M, de Maertelaer V, Staroukne M, et al. Increased angiotensin II in ascites during severe ovarian hyperstimulation syndrome: role of early pregnancy and ovarian gonadotropin stimulation. Fertil Steril. 1997;67:1038–45.

9. Morris RS, Wong IL, Kirkman E, Gentschein E, Paulson RJ, 11. Selman H, Brusco GF, Fioni F, Barnocchi N, Mariani E, El-Danassouri I. Vitrification is a highly efficient method to cryopreserve human embryos in vitro fertilization patients at high risk of developing ovarian hyperstimulation syndrome. Fertil Steril. 2009;91:1611–3.

10. Peng Z, Liu N. Cumulative live birth rates after frozen embryo transfer and fresh embryo transfer with oocyte numbers more than 15. J South China Univ. 2011;14:158–63.

11. Huddleston HG, Racovics C, Jackson KV, Fox JH, Ginsburg ES. Coasting vs. Cryopreservation of all embryos for prevention of ovarian hyperstimulation syndrome in vitro fertilization. Fertil Steril. 2008;90:1259–62.

12. Al-Shawaf T, Zosmer A, Hussain S, Tozer A, Panay N, Wilson C, et al. Prevention of severe ovarian hyperstimulation syndrome: a randomized controlled trial. Fertil Steril. 2011;96:1384–90.

13. Gurgan T, Demiroi A, Guven S, Benkalifa M, Girgin B, Li TC. Intravenous calcium infusion as a novel preventive therapy of ovarian hyperstimulation syndrome for patients with polycystic ovarian syndrome. Fertil Steril. 2011;96:53–7.

14. Palomba S, Falbo A, Carrillo L, Villani MT, Orri F, Russo T, et al. MET-formin in High Responder Italian Group. Metformin reduces risk of ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome during gonadotropin-stimulated in vitro fertilization cycles: a randomized, controlled trial. Fertil Steril. 2011;96:1384–90.

15. Gurgan T, Guo H, Shen Y, Li J, Liu G, Lin G. Reproductive analysis of treatment for severe ovari hyperstimulation syndrome complicated by pleural effusion and ascites. J Cent South Univ. 2012;3:720–4.

16. Aboughar M. Prediction of ovarian hyperstimulation syndrome (OHSS). Estradiol level has an important role in the prediction of OHSS. Hum Reprod. 2003;18:1140–1.

17. Garcia-Velasco JA, Moreno L, Pacheco A, Guillen A, Duque L, Requena A, et al. The aromatase inhibitor letrozole increases the concentration of intraovarian androgens and improves in vitro fertilization outcome in low responder patients: a pilot study. Fertil Steril. 2005;84:82–7.

18. Garcia-Velasco JA, Quea G, Piro M, Mayoral R, Ruiz M, Toribio M, et al. Letrozole administration during the luteal phase after ovarian stimulation impacts corpus luteum function: A randomized, placebo-controlled trial. Fertil Steril. 2009;92:222–5.

19. Fatemi HM, Popovic-Todorovic B, Donos O, Papankikou E, Smitz J, Devroye P. Luteal phase oestradiol suppression by letrozole: a pilot study in oocyte donors. Reprod Biomed Online. 2008;17:307–11.

20. Mai QY, Hu XK, Yang G, Luo Y, Huang KJ, Yuan Y, Zhou CQ. Effect of letrozole on moderate and severe early-onset ovarian hyperstimulation syndrome in high-risk women: a prospective randomized trial. Am J Obstet Gynecol. 2017;216(42):e1–10.

21. He QH, Liang LL, Zhang CL, Li HS, Ge ZJ, Wang L, et al. Effects of different doses of letrozole on the incidence of early-onset ovarian hyperstimulation syndrome after oocyte retrieval. Syst Biol Reprod Med. 2014;60:355–60.

22. He QH, Xu JN, Cui SH, Li HS, Zhang CL. Relationship between luteinization during the luteal phase after oocyte retrieval and the early-stage ovarian hyperstimulation syndrome occurrence. Chin J Obstet Gynecol. 2014;49:909–13.

23. Yu ZJ. The clinical research of letrozole on the treatment of ovarian hyperstimulation syndrome. Master’s thesis of Anhui Medical University. 2017.

24. Zhang L, Li P, Lin J, He XM, Shi YY, Ye YP, et al. Clinical effect analysis of letrozole on preventing ovarian hyperstimulation syndrome after oocyte retrieval. J Practical Obstet Gynecol. 2017;33:363–5.

25. Wang YQ, Yang J, Xu WM, Xie QZ, Yan WJ, Yin TL, et al. Uterine luteal administration decreases serum estrogen level but not the risk of ovarian hyperstimulation syndrome. J Peking Univ. 2013;35:869–72.

26. Wang YQ, Luo J, Xu WM, Xie QZ, Yan WJ, Wu GX, et al. Can steroid ovarian suppression during the luteal phase after oocyte retrieval reduce the risk of severe OHSS? J Obstet Gynecol Res. 2015;41:63.

27. Lin J, Li P, Sha YM, Shi YY, Deng BB, Ye YP. Prevention of ovary hyperstimulation syndrome using letrozole after oocyte retrieval. Mater Child Health Care China. 2016;31:117–8.

28. Wells G, SBD. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of non-randomised Studies in meta-analysis. In: Proceedings or the Third Symposium on Systematic Reviews beyond the Basics. Improving Quality and Impact, Oxford, 3–5 July 2000.

29. Golan A, Ron-El R, Herman A, Soffer Y, Weinraub Z, Caspi E. Ovarian hyperstimulation syndrome: an update review. Obstet Gynecol Surv. 1989;44:430–40.

30. Navot D, Bergh PA, Laufer N. Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertil Steril. 1992;58:249–61.

31. Jarkovská K, Kubcová Skalniková H, Halada P, Habáková R, Moos J, Rezabek K, et al. Development of ovarian hyperstimulation syndrome: interrogation of key proteins and biological processes in human follicular fluid of women undergoing in vitro fertilization. Mol Hum Reprod. 2011;17:679–92.

32. Soares SR. Etiology of OHSS and use of dopamine agonists. Fertil Steril. 2012;97:517–22.

33. Delvigne A. Symposium: Update on prediction and management of OHSS. Epidemiology of OHSS Reprod Biomed Online. 2009;19:8–13.
44. Asch RH, Li HP, Balmaceda JP, Weckstein LN, Stone SC. Severe ovarian hyperstimulation syndrome in assisted reproductive technology: definition of high risk group. Hum Reprod. 1991;6:1395–9.
45. Abdallah R, Kligman I, Davis O, Rosenwaks Z. Withholding gonadotropins until human chorionic gonadotropin administration. Semin Reprod Med. 2010;28:486–92.
46. Papanikolaou EG, Polyzos NP, Humaidan P, Pados G, Bosch E, Tournaye H, et al. Aromatase inhibitors in stimulated IVF cycles. Reprod Biodocrinol. 2011;9:85.
47. Li YP, Zhang Q, Zhou QE, Liu DE, Liu NH, Deng L, Chen XH. Clinical study on letrozole for induction of ovulation.
48. Practice Committee of the American Society for Reproductive Medicine. Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guideline. Fertil Steril. 2016;106:1634–47.
49. Agrawal R, Tan SL, Wild S, Sladkevicius P, Engmann L, Payne N, et al. Serum vascular endothelial growth factor concentrations in in vitro fertilization cycles predict the risk of ovarian hyperstimulation syndrome. Fertil Steril. 1999;71:287–93.
50. Abramov Y, Barak V, Nisman B, Schenker JG. Vascular endothelial growth factor plasma levels correlate to the clinical picture in severe ovarian hyperstimulation syndrome. Fertil Steril. 1997;67:261–5.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.